ACE and cardiovascular disorder: Given the high global prevalence of cardiovascular disease and the use of ACE inhibitors for first‐line treatment (Stapff & Hilderbrand, 2019), it is crucial to develop ACE inhibitors with better safety profiles and/or novel mechanisms of action.